Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 518281, 9 pages
http://dx.doi.org/10.1155/2015/518281
Review Article

Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival

The Mater Private Hospital, Eccles Street, Dublin, Ireland

Received 24 March 2015; Revised 28 May 2015; Accepted 25 June 2015

Academic Editor: Dimitris S. Ladas

Copyright © 2015 K. E. O’Sullivan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Pennathur, M. K. Gibson, B. A. Jobe, and J. D. Luketich, “Oesophageal carcinoma,” The Lancet, vol. 381, no. 9864, pp. 400–412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Zhang, “Epidemiology of esophageal cancer,” World Journal of Gastroenterology, vol. 19, no. 34, pp. 5598–5606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Portale, J. A. Hagen, J. H. Peters et al., “Modern 5-year survival of resectable esophageal adenocarcinoma: single institution experience with 263 patients,” Journal of the American College of Surgeons, vol. 202, no. 4, pp. 588–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. E. F. Parker, H. B. Gregorie Jr., J. E. Arrants, and J. M. Ravenel, “Carcinoma of the esophagus,” Annals of Surgery, vol. 171, no. 5, pp. 746–751, 1970. View at Publisher · View at Google Scholar · View at Scopus
  5. K. S. Kwatra, B. R. Prabhakar, S. Jain, and J. S. Grewal, “Sarcomatoid carcinoma (carcinosarcoma) of the esophagus with extensive areas of osseous differentiation: a case report,” Indian Journal of Pathology & Microbiology, vol. 46, no. 1, pp. 49–51, 2003. View at Google Scholar · View at Scopus
  6. L. M. Brown, S. S. Devesa, and W.-H. Chow, “Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age,” Journal of the National Cancer Institute, vol. 100, no. 16, pp. 1184–1187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. R. Siewert and H. J. Stein, “Classification of adenocarcinoma of the oesophagogastric junction,” The British Journal of Surgery, vol. 85, no. 11, pp. 1457–1459, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Fitzgerald, B. A. Onwuegbusi, M. Bajaj-Elliott, I. T. Saeed, W. R. Burnham, and M. J. G. Farthing, “Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants,” Gut, vol. 50, no. 4, pp. 451–459, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Solaymani-Dodaran, R. F. A. Logan, J. West, T. Card, and C. Coupland, “Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux,” Gut, vol. 53, no. 8, pp. 1070–1074, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. G. W. Falk, “Risk factors for esophageal cancer development,” Surgical Oncology Clinics of North America, vol. 18, no. 3, pp. 469–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. X. B. D'Journo and P. A. Thomas, “Current management of esophageal cancer,” Journal of Thoracic Disease, vol. 6, supplement 2, pp. S253–S264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. Boonstra, T. C. Kok, B. P. L. Wijnhoven et al., “Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial,” BMC Cancer, vol. 11, article 181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Cunningham, W. H. Allum, S. P. Stenning et al., “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” The New England Journal of Medicine, vol. 355, no. 1, pp. 11–20, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. P. van Hagen, M. C. C. M. Hulshof, J. J. B. van Lanschot et al., “Preoperative chemoradiotherapy for esophageal or junctional cancer,” The New England Journal of Medicine, vol. 366, no. 22, pp. 2074–2084, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. G. Urba, M. B. Orringer, A. Turrisi, M. Iannettoni, A. Forastiere, and M. Strawderman, “Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 305–313, 2001. View at Google Scholar · View at Scopus
  16. T. N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T. P. J. Hennessy, “A comparison of multimodal therapy and surgery for esophageal adenocarcinoma,” The New England Journal of Medicine, vol. 335, no. 7, pp. 462–467, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Sundaram, A. Srinivasan, S. Baker, and S. K. Mittal, “Readmission and risk factors for readmission following esophagectomy for esophageal cancer,” Journal of Gastrointestinal Surgery, vol. 19, no. 4, pp. 581–586, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. C. L. Donohoe, N. J. O'Farrell, T. Grant et al., “Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard,” Annals of Surgery, vol. 258, no. 5, pp. 784–792, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. P. Barbour, M. Jones, M. Gonen et al., “Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response,” Annals of Surgical Oncology, vol. 15, no. 10, pp. 2894–2902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. L. R. Chirieac, S. G. Swisher, J. A. Ajani et al., “Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation,” Cancer, vol. 103, no. 7, pp. 1347–1355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. M. Donahue, F. C. Nichols, Z. Li et al., “Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival,” Annals of Thoracic Surgery, vol. 87, no. 2, pp. 392–399, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A.-M. Mandard, F. Dalibard, J.-C. Mandard et al., “Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations,” Cancer, vol. 73, no. 11, pp. 2680–2686, 1994. View at Google Scholar · View at Scopus
  23. K. L. Meredith, J. M. Weber, K. K. Turaga et al., “Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer,” Annals of Surgical Oncology, vol. 17, no. 4, pp. 1159–1167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. K. Kim, K.-J. Cho, S.-I. Park et al., “Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 1, pp. 115–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Schneider, S. E. Baldus, R. Metzger et al., “Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification,” Annals of Surgery, vol. 242, no. 5, pp. 684–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. J. S. Donington, D. L. Miller, M. S. Allen, C. Deschamps, F. C. Nichols III, and P. C. Pairolero, “Tumor response to induction chemoradiation: influence on survival after esophagectomy,” European Journal of Cardio-Thoracic Surgery, vol. 24, no. 4, pp. 631–637, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. H. Lin, J. Wang, P. K. Allen et al., “A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer,” Journal of Gastrointestinal Oncology, vol. 6, no. 1, pp. 45–52, 2015. View at Google Scholar
  28. H. D. Skinner, J. H. Lee, M. S. Bhutani et al., “A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma,” Cancer, vol. 120, no. 23, pp. 3635–3641, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Wen, H. Yang, M. Z. Liu et al., “Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy,” Annals of Oncology, vol. 25, no. 9, pp. 1769–1774, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Hsu, J. Chia-Hsien Cheng, Y. Chang, J. Lee, A. C. Koong, and E. Y. Chuang, “Circulating mRNA profiling in esophageal squamous cell carcinoma identifies FAM84B as a biomarker in predicting pathological response to neoadjuvant chemoradiation,” Scientific Reports, vol. 5, Article ID 10291, 2015. View at Publisher · View at Google Scholar
  31. J. Douville, R. Beaulieu, and D. Balicki, “ALDH1 as a functional marker of cancer stem and progenitor cells,” Stem Cells and Development, vol. 18, no. 1, pp. 17–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Ginestier, M. H. Hur, E. Charafe-Jauffret et al., “ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome,” Cell Stem Cell, vol. 1, no. 5, pp. 555–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. A. Ajani, X. Wang, S. Song et al., “ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients,” Molecular Oncology, vol. 8, no. 1, pp. 142–149, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. U. Heger, S. Blank, C. Wiecha et al., “Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?” Annals of Surgical Oncology, vol. 21, no. 5, pp. 1739–1748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. V. R. Patel, W. L. Hofstetter, A. M. Correa et al., “Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation,” The Annals of Thoracic Surgery, vol. 98, no. 3, pp. 1064–1071, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. G. H. Porteous, J. M. Neal, A. Slee, H. Schmidt, and D. E. Low, “A standardized anesthetic and surgical clinical pathway for esophageal resection: impact on length of stay and major outcomes,” Regional Anesthesia and Pain Medicine, vol. 40, no. 2, pp. 139–149, 2015. View at Publisher · View at Google Scholar
  37. R. E. Merritt, R. I. Whyte, N. T. D'Arcy, C. D. Hoang, and J. B. Shrager, “Morbidity and mortality after esophagectomy following neoadjuvant chemoradiation,” The Annals of Thoracic Surgery, vol. 92, no. 6, pp. 2034–2040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. C. Berger, W. J. Scott, G. Freedman et al., “Morbidity and mortality are not increased after induction chemoradiotherapy followed by esophagectomy in patients with esophageal cancer,” Seminars in Oncology, vol. 32, no. 6, supplement 9, pp. S16–S20, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. T. A. D'Amico, “Outcomes after surgery for esophageal cancer,” Gastrointestinal Cancer Research, vol. 1, no. 5, pp. 188–196, 2007. View at Google Scholar
  40. B. Kayani, K. Okabayashi, H. Ashrafian et al., “Does obesity affect outcomes in patients undergoing esophagectomy for cancer? A meta-analysis,” World Journal of Surgery, vol. 36, no. 8, pp. 1785–1795, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. D. E. Low, D. Alderson, I. Cecconello et al., “International consensus on standardization of data collection for complications associated with esophagectomy: Esophagectomy Complications Consensus Group (ECCG),” Annals of Surgery, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Wang, N. Eldridge, M. L. Metersky et al., “National trends in patient safety for four common conditions, 2005–2011,” The New England Journal of Medicine, vol. 370, no. 4, pp. 341–351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. M. I. Braghetto, H. G. Cardemil, B. C. Mandiola, L. G. Masia, and S. F. Gattini, “Impact of minimally invasive surgery in the treatment of esophageal cancer,” Arquivos Brasileiros de Cirurgia Digestiva, vol. 27, no. 4, pp. 237–242, 2014. View at Publisher · View at Google Scholar
  44. J. F. Finks, N. H. Osborne, and J. D. Birkmeyer, “Trends in hospital volume and operative mortality for high-risk surgery,” The New England Journal of Medicine, vol. 364, no. 22, pp. 2128–2137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Wang, Y. Shen, M. Feng et al., “Outcomes, quality of life, and survival after esophagectomy for squamous cell carcinoma: a propensity score–matched comparison of operative approaches,” The Journal of Thoracic and Cardiovascular Surgery, vol. 149, no. 4, pp. 1006–1015.e4, 2015. View at Publisher · View at Google Scholar
  46. O. C. Burdall, A. P. Boddy, J. Fullick et al., “A comparative study of survival after minimally invasive and open oesophagectomy,” Surgical Endoscopy, vol. 29, no. 2, pp. 431–437, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Y. Park, D. J. Kim, W. S. Yu, and H. S. Jung, “Robot-assisted thoracoscopic esophagectomy with extensive mediastinal lymphadenectomy: experience with 114 consecutive patients with intrathoracic esophageal cancer,” Diseases of the Esophagus, 2015. View at Publisher · View at Google Scholar
  48. L. Chen, F. Liu, K. Wang, and W. Zou, “Omentoplasty in the prevention of anastomotic leakage after oesophagectomy: a meta-analysis,” European Journal of Surgical Oncology, vol. 40, no. 12, pp. 1635–1640, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Markar, C. Gronnier, A. Duhamel et al., “Pattern of postoperative mortality after esophageal cancer resection according to center volume: results from a large european multicenter study,” Annals of Surgical Oncology, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. J. D. Luketich, A. Pennathur, Y. Franchetti et al., “Minimally invasive esophagectomy: results of a prospective phase II multicenter trial—the Eastern Cooperative Oncology Group (E2202) study,” Annals of Surgery, vol. 261, no. 4, pp. 702–707, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. C. M. Jones, R. Heah, B. Clarke, and E. A. Griffiths, “Should routine radiological assessment of anastomotic integrity be performed after oesophagectomy with cervical anastomosis? Best evidence topic (BET),” International Journal of Surgery, vol. 15, pp. 90–94, 2015. View at Publisher · View at Google Scholar
  52. J. Guo, X. Chu, Y. Liu, N. Zhou, Y. Ma, and C. Liang, “Choice of therapeutic strategies in intrathoracic anastomotic leak following esophagectomy,” World Journal of Surgical Oncology, vol. 12, article 402, 2014. View at Publisher · View at Google Scholar
  53. L. Schaheen, S. H. Blackmon, and K. S. Nason, “Optimal approach to the management of intrathoracic esophageal leak following esophagectomy: a systematic review,” American Journal of Surgery, vol. 208, no. 4, pp. 536–543, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. Y. Taniyama, G. Miyata, T. Kamei et al., “Complications following recurrent laryngeal nerve lymph node dissection in oesophageal cancer surgery,” Interactive Cardiovascular and Thoracic Surgery, vol. 20, no. 1, pp. 41–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Hoshino, K. Kawada, Y. Nakajima, K. Nagai, T. Sugimoto, and T. Kawano, “Vocal cord assessment with transnasal endoscopy in intubated patients after esophagectomy,” Journal of Medical and Dental Sciences, vol. 61, no. 1, pp. 17–22, 2014. View at Google Scholar · View at Scopus
  56. J. M. Reinersman, M. S. Allen, C. Deschamps et al., “External validation of the Ferguson pulmonary risk score for predicting major pulmonary complications after oesophagectomydagger,” European Journal of Cardio-Thoracic Surgery, 2015. View at Publisher · View at Google Scholar
  57. T. Rackley, T. Leong, M. Foo, and T. Crosby, “Definitive chemoradiotherapy for oesophageal cancer—a promising start on an exciting journey,” Clinical Oncology, vol. 26, no. 9, pp. 533–540, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Sheahan, “Management of advanced laryngeal cancer,” Rambam Maimonides Medical Journal, vol. 5, no. 2, Article ID e0015, 2014. View at Publisher · View at Google Scholar
  59. J. L.-Y. Chen, C.-Y. Huang, Y.-S. Huang et al., “Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy,” Acta Obstetricia et Gynecologica Scandinavica, vol. 93, no. 7, pp. 661–668, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Ogura, A. Chino, T. Konishi et al., “Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response,” International Journal of Colorectal Disease, vol. 30, no. 3, pp. 367–373, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Y. B. Teoh, P. W. Y. Chiu, W. K. Yeung, S. Y. W. Liu, S. K. H. Wong, and E. K. W. Ng, “Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial,” Annals of Oncology, vol. 24, no. 1, Article ID mds206, pp. 165–171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Herskovic, K. Martz, M. Al-Sarraf et al., “Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus,” The New England Journal of Medicine, vol. 326, no. 24, pp. 1593–1598, 1992. View at Publisher · View at Google Scholar · View at Scopus
  63. B. D. Minsky, T. F. Pajak, R. J. Ginsberg et al., “INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy,” Journal of Clinical Oncology, vol. 20, no. 5, pp. 1167–1174, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. J. D. Urschel and H. Vasan, “A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer,” American Journal of Surgery, vol. 185, no. 6, pp. 538–543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Fiorica, D. di Bona, F. Schepis et al., “Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis,” Gut, vol. 53, no. 7, pp. 925–930, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. V. Gebski, B. Burmeister, B. M. Smithers, K. Foo, J. Zalcberg, and J. Simes, “Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis,” The Lancet Oncology, vol. 8, no. 3, pp. 226–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Stahl, M. Stuschke, N. Lehmann et al., “Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2310–2317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Conroy, M.-P. Galais, J.-L. Raoul et al., “Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial,” The Lancet Oncology, vol. 15, no. 3, pp. 305–314, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. B. N. Ruppert, J. M. Watkins, K. Shirai et al., “Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer,” The American Journal of Clinical Oncology, vol. 33, no. 4, pp. 346–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Wang, J. Ryu, D. Gandara et al., “A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer,” Journal of Thoracic Oncology, vol. 2, no. 2, pp. 153–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Bedenne, P. Michel, O. Bouché et al., “Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102,” Journal of Clinical Oncology, vol. 25, no. 10, pp. 1160–1168, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Crosby, C. N. Hurt, S. Falk et al., “Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial,” The Lancet Oncology, vol. 14, no. 7, pp. 627–637, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. J. M. Blazeby, S. Strong, J. L. Donovan et al., “Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer,” British Journal of Cancer, vol. 111, no. 2, pp. 234–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. R. Jang, G. Darling, and R. K. Wong, “Multimodality approaches for the curative treatment of esophageal cancer,” Journal of the National Comprehensive Cancer Network, vol. 13, no. 2, pp. 229–238, 2015. View at Google Scholar
  75. V. E. Strong, T. A. D'Amico, L. Kleinberg, and J. Ajani, “Impact of the 7th edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers,” Journal of the National Comprehensive Cancer Network, vol. 11, no. 1, pp. 60–66, 2013. View at Google Scholar · View at Scopus
  76. J. A. Elliott, N. J. O'Farrell, S. King et al., “Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma,” The British Journal of Surgery, vol. 101, no. 13, pp. 1702–1711, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. T. Klayton, T. Li, J. Q. Yu et al., “The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma,” Journal of Gastrointestinal Cancer, vol. 43, no. 4, pp. 612–618, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Myslivecek, C. Neoral, R. Vrba et al., “The value of (1)(8)F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 156, no. 2, pp. 171–179, 2012. View at Google Scholar
  79. J. S. Park, J. Y. Choi, S. H. Moon et al., “Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma,” Cancer Research and Treatment, vol. 45, no. 1, pp. 22–30, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. N. K. S. Cheedella, A. Suzuki, L. Xiao et al., “Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort,” Annals of Oncology, vol. 24, no. 5, pp. 1262–1266, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Kukar, R. M. Alnaji, F. Jabi et al., “Role of repeat 18F-fluorodeoxyglucose positron emission tomography examination in predicting pathologic response following neoadjuvant chemoradiotherapy for esophageal adenocarcinoma,” JAMA Surgery, vol. 150, no. 6, pp. 555–562, 2015. View at Publisher · View at Google Scholar
  82. U. Metser, F. Rashidi, H. Moshonov et al., “18F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer,” Annals of Nuclear Medicine, vol. 28, no. 4, pp. 295–303, 2014. View at Publisher · View at Google Scholar · View at Scopus